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Abstract 
Introduction: Enterohepatic circulation (EHC) of conjugated bile acids is an important physiological process 
crucial for regulation of intracellular concentrations of bile acids and their function as detergents and signal 
carriers. Only few bile acid-derived imaging agents have been synthesized and hitherto none have been 
evaluated for studies of EHC. We hypothesized that N-(4-[18F]fluorobenzyl)cholylglycine ([18F]FBCGly), a 
novel fluorine-18 labeled derivative of endogenous cholylglycine, would be a suitable tracer for PET of the 
EHC of conjugated bile acids, and we report here a radiosynthesis of [18F]FBCGly and a proof-of-concept 
study by PET/MR in rats. 
Methods: A radiosynthesis of [18F]FBCGly was developed based on reductive alkylation of glycine with 4-
[18F]fluorobenzaldehyde followed by coupling to cholic acid. [18F]FBCGly was investigated in vivo by 
dynamic PET/MR in anaesthetized rats; untreated or treated with cholyltaurine or rifampicin. Possible in 
vivo metabolites of [18F]FBCGly were investigated by blood and bile sampling, and the stability of 
[18F]FBCGly towards enzymatic de-conjugation by Cholylglycine Hydrolase was tested in vitro. 
Results: [18F]FBCGly was produced with a radiochemical purity of 96% ± 1% and a non-decay corrected 
radiochemical yield of 1.0% ± 0.3% (mean ± SD; n = 12). PET/MR studies showed that i.v.-administrated 
[18F]FBCGly underwent EHC within 40–60 min with a rapid transhepatic transport from blood to bile. In 
untreated rats, the radioactivity concentration of [18F]FBCGly was approximately 15 times higher in bile 
than in liver tissue. Cholyltaurine and rifampicin inhibited the biliary secretion of [18F]FBCGly. No fluorine-18 
metabolites of [18F]FBCGly were observed. 
Conclusion: We have developed a radiosynthesis of a novel fluorine-18 labeled bile acid derivative, 
[18F]FBCGly, and shown by PET/MR that [18F]FBCGly undergoes continuous EHC in rats without 
metabolizing. This novel tracer may prove useful in PET studies on the effect of drugs or diseases on the 
EHC of conjugated bile acids. 
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1. Introduction 
The formation of bile acids in the liver and their secretion into bile canaliculi and onwards into the small 
intestine play an essential role in digestion and detoxification, and in metabolic signaling [1-3]. Before 
secretion from hepatocytes, bile acids are conjugated (N-acyl amidated) with glycine or taurine. Less than 
10% of the secreted bile acids stem from de novo synthesis; the rest have undergone enterohepatic 
circulation (EHC), i.e. the continuous circulation of bile acids between liver and small intestine [1, 2, 4]. The 
EHC, which occurs 6–10 times per day in humans [5], results from active vectorial transport of bile acids 
across hepatocyte and enterocyte membranes, and involves several transporter proteins [6]. These 
proteins include the Bile Salt Export Pump (BSEP), which accounts for the rate-limiting step of the overall 
transport across the hepatocyte [7], and the Apical Sodium-dependent Bile acid Transporter (ASBT), which 
is located mainly in ileal enterocytes and accounts for more than 90% of the absorption of bile acids from 
the intestinal lumen [8, 9]. The EHC ensures optimal concentrations of bile acids at the sites of their 
physiologic actions and hence allows bile acids to form micelles and dissolve digested lipids in the small 
intestine and to function as signal molecules, while keeping the intracellular concentration of bile acids low 
to avoid cellular damages [1, 10]. Several factors may perturb the EHC and lead to liver and gastrointestinal 
disorders [2, 11-13]. Cholestatic liver diseases and drug-induced inhibition of BSEP result in accumulation of 
bile acids in hepatocytes, which leads to liver injury, treatable only by liver transplantation in severe cases 
[7, 14]. Impaired intestinal uptake caused by lack of the ileum or by drug-induced inhibition of ASBT results 
in bile acid malabsorption and excessive excretion of bile acids to the colon, which leads to severe diarrhea, 
alteration of the gut microbiome and, potentially, development of colorectal cancer [13]. 
 
A method for non-invasive quantitative imaging of the dynamic EHC of conjugated bile acids in vivo would 
be a valuable tool for investigations of the underlying pathological mechanisms of diseases that affect the 
EHC and of drugs inhibiting hepatic and intestinal transport of conjugated bile acid. 
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The development of such method is likely to be successful only if the imaging agent is derived from an 
endogenous bile acid conjugate, since these are the only molecules that so far have been shown to go 
through all features of the EHC [10]. The current standard of practice for quantification of the EHC do 
involve an analog, 23-[75Se]seleno-25-homotaurocholic acid, closely related to endogenous cholyltaurine, 
but the method provides only a measure of the retention of the labeled analog in the body; not 
quantifiable images of its circulation between liver and ileum [15]. Other labeled bile acid analogs have 
been investigated for single photon emission computed tomography [16], magnetic resonance [17-19], and 
PET imaging [20-26], but so far no imaging agent has been reported for imaging of the EHC. In particular, 
[11C]cholylsarcosine, a carbon-11 labeled analog of endogenous cholylglycine [20], has proven useful for 
quantification of hepatic transport of conjugated bile acids in healthy persons and in patients with 
cholestatic liver disease by PET/CT [27, 28]. However, although cholylsarcosine is known to undergo EHC, 
the use [11C]cholylsarcosine as PET tracer for EHC is limited by the relatively short half-life of the carbon-11 
radioisotope (11C; T½ = 20.3 min). We therefore set out to develop a novel bile acid tracer with properties 
comparable to [11C]cholylsarcosine, but labeled with a positron emitting isotope with a radioactive half-life 
suitable for studies of EHC. Here we report a radiosynthesis of N-(4-[18F]fluorobenzyl)cholylglycine 
([18F]FBCGly), a novel fluorine-18 (18F; half-life = 109.8 min) labeled derivative of endogenous cholylglycine, 
and show in a proof-of-concept study in rats that [18F]FBCGly is a PET tracer for EHC. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5 
 
2. Materials and methods  
2.1 General information 
Chemicals and solvents were obtained from Sigma-Aldrich or VWR International Ltd and used as received. 
Water was sterile or MilliQ water. Cholylglycine Hydrolase from Clostridium perfringens (C. welchii) 
(lyophilized powder, ≥100 units/mg) was obtained from Sigma-Aldrich. Cholylglycine-2,2,4,4-d4 was 
obtained from CDN Isotopes. (4-Formylphenyl)trimethylammonium triflate [29] and unlabeled 
cholylsarcosine [20] were prepared as described in the literature. 4-Fluorobenzylalcohol (used for 
identification purposes only) was prepared by reduction of 4-fluorobenzaldehyde with sodium borohydride 
in methanol. Unlabeled N-(4-fluorobenzyl)glycine methyl ester (FBGly-ME),  N-(4-fluorobenzyl)cholylglycine 
methyl ester (FBCGly-ME), and N-(4-fluorobenzyl)cholylglycine (FBCGly) were prepared and characterized 
(1H, 13C, 19F, COSY, HSQC, HMBC and ROESY NMR) as described in Supplementary Material. For comparison, 
NMR spectra of cholic acid are also reported. Sep-Pak® Accell Plus QMA Carbonate Plus Light Cartridge (130 
mg sorbent/cartridge, 37–55 µm particle size) and Sep-Pak® Alumina N Plus Light Cartridges (280 mg 
sorbent/cartridge, 50–300 µm particle size) were obtained from Waters® and used as received. Sep-Pak® C8 
Plus Short Cartridges (400 mg sorbent/cartridge, 37–55 m particle size), also obtained from Waters®, were 
conditioned before use with 10 mL ethanol, then 10 mL water, and finally 10 mL air.  
  
2.2 Radiochemistry 
The developed radiosynthesis of [18F]FBCGly is illustrated in Fig. 1. No-carrier-added [18F]fluoride was 
produced by the 18O(p,n)18F nuclear reaction from irradiation of isotopically enriched [18O]H2O (Rotem 
Industries, Deer Sheva, Israel) using a cyclotron (GE PETtrace 16.4-MeV proton beam or IBA Cyclone 18/18). 
The [18F]fluoride (40–60 GBq) was trapped on a QMA cartridge and eluted into a 3 mL reaction vessel with a 
solution of K222 (Kryptofix™; 5 mg; 13 µmol) and K2CO3 (0.7 mg ; 5 µmol) in a mixture of water (0.30 mL) 
and acetonitrile (0.30 mL). The [18F]fluoride was dried in the reactor by azeotropic distillation from 
anhydrous acetonitrile (3x0.6 mL) under a stream of helium at 120 oC. The temperature was lowered to 80 
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oC, a solution of (4-formylphenyl)trimethylammonium triflate (2 mg; 6 µmol) in anhydrous 
dimethylsulfoxide (0.3 mL) was added, and the mixture was heated at 105 oC for 10 min. The crude [18F]FBA 
(dark orange to brown in color) was purified by passing it through an alumina N cartridge, which was 
subsequently washed with anhydrous dimethylsulfoxide (0.2 mL), into a second 3 mL reaction vessel. A 
solution of glycine methyl ester hydrochloride (2 mg; 16 µmol) and triethylamine (3 µL; 22 µmol) in 
anhydrous dimethylsulfoxide (0.1 mL) was added to the purified [18F]FBA and the mixture was heated at 60 
oC for 10 min. The reaction vessel was cooled to 25 oC using a stream of cold air, a solution of NaBH4 (2 mg; 
53 µmol) in anhydrous dimethylsulfoxide (0.1 mL) was added, and the mixture was allow to stand for 5 min. 
A solution of cholic acid (16 mg; 39 µmol) and triethylamine (9 µL; 65 µmol) in anhydrous dimethylsulfoxide 
(0.1 mL) was added, followed by a solution of diethyl phosphoryl cyanide (12 µL; 79 µmol) in anhydrous 
dimethylsulfoxide (0.1 mL). The temperature was raised to 60 oC and the mixture was heated for 10 min. All 
added solutions were freshly prepared. After cooling to 25 oC, the reaction mixture was diluted with water 
(9 mL) and [18F]FBCGly-ME was trapped on a conditioned C8 cartridge. The cartridge was washed with water 
(10 mL) and 50% aqueous ethanol (10 mL), and eluted with 100% ethanol (1 mL) into a product vial. 
Aqueous NaOH (2 mL; 0.25 N) was added to the product vial and the mixture was allowed to stand at room 
temperature for 10 min with occasional shaking. The basic mixture was finally neutralized with aqueous 
NaH2PO4 (7 mL; 70 mM). Total synthesis time was 90 min from delivery of [
18F]fluoride. 
   
The product formulation of [18F]FBCGly was analyzed by reverse-phase HPLC with a PDA-detector (Dionex 
Ultimate® 3000 system) connected in series with a gamma-detector (Gabistar; Nuclear Interface) and an ESI 
mass spectrometer (Bruker Daltonics HCT Plus ion trap mass spectrometer) running in negative ionization 
mode. The column was a Phenomenex® Luna® 5µ C18(2) 100A (5 µm, 150x4.6 mm) with an isocratic eluent 
of 50% acetonitrile in aqueous 1 mM NH4OAc (pH 3.0; adjusted with glacial acetic acid) and a flow of 1 
mL/min. The product formulation of [18F]FBCGly was also tested for free [18F]fluoride by radio-iTLC 
(Supplementary Material). The identity of [18F]FBCGly (retention time: 8.2 min) was confirmed by co-
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injection of unlabeled reference material by monitoring its UV (254 nm) and MS (572.3 m/z) signals. For 
determination of molar radioactivity, the amount of FBCGly was determined by MS using a series of 
standard solutions (2, 5, 10, and 20 µg/mL) and with cholylglcyine 2,2,4,4-d4 as internal standard. To 
investigate the individual steps of the radiosynthesis, the formation of reaction intermediates was analyzed 
by radio-HPLC (Supplementary Material). 
  
2.3 In vivo PET/MR and metabolite studies 
All animal experiments were carried out at the Dept. of Nuclear Medicine & PET Centre, Aarhus University 
Hospital, Aarhus, Denmark. The animal experiments were performed according to the Danish Animal 
Experimentation Act and the European convention for the protection of vertebrate animals used for 
experimental and other purposes (European Treaty Series no. 123). Prior to the experiments, female 
Sprague-Dawley rats (n = 10; 208 – 333 g) were kept in a temperature and light-controlled environment and 
provided with standard food and water ad libitum. For the duration of the experiments, the animals were 
positioned on the heat-controlled (37 oC) bed and kept under general anesthesia with 2% isoflurane 
(IsoFlo® vet 100%, Zoetis) in air (1.5 L/min atmospheric air and 0.5 L/min O2). [
18F]FBCGly was administrated 
as a single bolus (19–35 MBq) through a 24 GA venflon (Neoflon, Becton Dickinson) in the tail vein. After 
completion of the experiments, the animals were euthanized with an overdose of sodium pentobarbital 
(Euthanimal, 400 mg/mL, Alfasan).  
 
PET/MR imaging of Rats 1–7 were performed using a small-animal PET/MR scanner (nanoScan, Mediso) 
with a transaxial PET field of view of 12 cm and a permanent 1 Tesla magnet for MR. Rats 1–3 were injected 
with [18F]FBCGly only, while Rat 4 and Rat 5 were co-injected with cholyltaurine (68 mg/kg) simultaneous 
with the tracer. Rat 6 and Rat 7 were given a constant infusion of rifampicin (2 mg/kg/min) in isotonic saline 
initiated 40 min before the start of the PET scan and maintained throughout the scan. PET scans were 
acquired in 3D list-mode for 120 minutes with the field of view of the PET camera covering abdomen and 
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the lower part of thorax. MR scans were recorded for definition of anatomic structures (T1 weighted) and 
for attenuation and scatter correction of the PET recordings. PET recordings were obtained with the energy 
window set to 400–600 keV. Corrections for dead-time, radioactivity decay, attenuation, random and 
scatter counts were done using the manufacturer' software. The dynamic images were obtained by sorting 
the list mode data into the following time frames: 8x15, 4x30, 2x60, 2x120, 4x300, and 9x600 sec. The 
images were reconstructed with an algorithm (Tera-Tomo 3D; median filtering period: iteration count) 
provided by the manufacturer. Volumes-of-interest for liver tissue (excluding large blood vessels and visible 
intrahepatic bile ducts) and bile duct were manually drawn using the PMOD software (PMOD Technologies) 
and used to generate time courses of radioactivity concentrations (reported as %ID/mL tissue vs. min, 
where ID is percent of injected dose). The radioactivity concentrations were decay corrected to the start of 
the scan. 
  
Rats 8–10 were investigated for possible in vivo metabolites of [18F]FBCGly. For Rat 8 and Rat 9,  blood 
samples were collected from the femoral artery 1, 2, 3, 5, 10, 30, 60, and 120 minutes after tracer 
administration for analysis of fluorine-18 metabolites in plasma. For Rat 10, the common bile duct was 
canaliculated (IntramedicTM, BD, PE 10 catheter, length 20 cm, inner diameter 0.28 cm) and samples were 
collected 0-15, 15-30, 30-45, 45-60, 60-75, 75-90, and 90-105 min after tracer administration for analysis of 
fluorine-18 metabolites in bile. Both plasma and bile samples were fractionated by reverse-phase HPLC (20 
min run with collection of 1 fraction/min). The column was a Phenomenex® Luna® 10 µ C18(2) 100A (10 
µm, 250x10 mm) with an isocratic eluent of 70% acetonitrile in aqueous 1 mM NH4OAc (pH 3.0; adjusted 
with glacial acetic acid) and a flow of 3 mL/min. With these conditions, non-metabolized [18F]FBCGly elutes 
in fractions 10–12. Each collected faction was measured in a well counter (Packard Biosciences). 
 
2.4 In vitro stability test of FBCGly towards enzymatic de-conjugation by Cholylglycine Hydrolase 
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The possible de-conjugation of FBCGly, cholylsarcosine, and cholylglycine, catalyzed by Cholylglycine 
Hydrolase, was investigated in vitro in two separate experiments using previously described conditions [30]: 
to a solution of the unlabeled conjugated bile acid (2 µM) in 0.25 M aqueous NaOAc buffer (0.4 mL; pH 5.6) 
were added 1.85% aqueous EDTA (0.2 mL), 0.87% aqueous mercaptoethanol (0.2 mL), and an aqueous 
suspension of Cholylglycine Hydrolase (0.2 mg; 0.2 mL). The mixture was incubated at 37 oC and samples 
were collected after 5 min, 15 min, 30 min, 1 hour, 2 hours, and 24 hours. The samples were analyzed by 
LC-MS as described for [18F]FBCGly and the relative amount of de-conjugation was determined from the 
amount of cholic acid formed. 
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3. Results 
3.1 Radiochemistry 
The developed radiosynthesis provided [18F]FBCGly (0.4–1.1 GBq) with a non-decay corrected 
radiochemical yield of 1.0% ± 0.3% (mean ± SD; n = 12; based on delivered [18F]fluoride) and a 
radiochemical purity of 96% ± 1% (mean ± SD; n = 12) (Fig. 2a and 2b). No free [18F]fluoride was detected in 
the formulation of [18F]FBCGly (Supplementary Material). The molar radioactivity of [18F]FBCGly was 
determined to 13 ± 2 GBq/µmol (mean ± SD; n = 4). In its formulation, a clear solution (pH 7–8) without any 
visible particles, [18F]FBCGly showed no alterations in chemical or radiochemical purity for up to 4 h after 
the end of synthesis. The first step of the radiosynthesis proceeded with a non-decay corrected yield of 
approximately 20% to give [18F]FBA with a radiochemical purity of ≥90% (Fig. 1; step i), while the 
condensation of [18F]FBA to glycine methyl ester followed by in situ reduction of the intermediate Schiff 
base by NaBH4 (steps ii and iii) proceeded with full conversion of [
18F]FBA to give 75% ± 4% (mean ± SD; n = 
5) [18F]FBGly-ME. The remaining radioactivity was found as 4-[18F]fluorobenzylalcohol (16% ± 8%; n = 5) and 
an unknown species (9% ± 6%; n = 5) (Table S1 in Supplementary Material). The in situ coupling of 
[18F]FBGly-ME with cholic acid (Fig. 1; step iv) proceeded to give [18F]FBCGly-ME  with a conversion of 62% ± 
8% (mean ± SD; n = 6) (Table S1). Only [18F]FBGly-ME reacted with cholic acid during this step; the by-
products 4-[18F]fluorobenzylalcohol and the unknown species were unreactive. Typical HPLC 
chromatograms are presented in Fig. 2c and 2d to illustrate the formation of reaction intermediates and by-
products during steps ii-iv of the radiosynthesis of [18F]FBCGly. The final step, basic hydrolysis of 
[18F]FBCGly-ME (Fig. 1; step v), proceeded with full conversion. To improve the overall radiochemical yield, 
we tested the effect of time by using 3 timer longer reaction times for steps ii–iv and included HPLC 
purification of [18F]FBA and [18F]FBCGly-ME. However, these modifications did not significantly improve the 
overall non-decay corrected radiochemical yield of the radiosynthesis (3% ± 1%; mean ± SD; n = 3) or the 
radiochemical purity of [18F]FBCGly (97% ± 1%; mean ± SD; n = 3). 
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3.2 In vivo PET/MR and metabolite studies 
Fig. 3 shows the result of a dynamic PET/MR recording after i.v. injection of [18F]FBCGly in an untreated rat 
(Rat 1). [18F]FBCGly was rapidly taken up into liver tissue within one minute after tracer administration 
followed by secretion into the bile duct within 2 minutes (Fig. 3a and 3b). The tracer subsequently 
dispersed into the small intestine and, about 20 min after administration, it had cleared liver tissue and bile 
duct and was visible only in the intestine (and in some cases also the stomach; presumably the result of 
relaxation of the pyloric valve caused by the anesthesia) (Fig. 3c and 3d). EHC of [18F]FBCGly was observed 
as the reappearance of radioactivity in liver tissue, bile duct, and duodenum approximately 55 min after 
tracer administration (Fig. 3e). No radioactivity was observed in the kidneys. Fig. 4 shows grouped time 
courses of radioactivity concentrations of [18F]FBCGly measured by PET in untreated rats (Rats 1–3), in rats 
treated with cholyltaurine (Rats 4 and 5), or in rats treated with rifampicin (Rats 6 and 7). Time courses for 
the individual animals are presented in Fig. S1 (Supplementary Material). In the liver tissue and bile duct of 
the untreated rats, the radioactivity concentrations peaked at 2 and 3 min, respectively, with a peak 
concentration in the bile duct approximately 15 times higher than that in liver tissue (Fig. 4). The 
radioactivity concentrations subsequently decreased rapidly to low concentrations within 25–30 min, and 
then increased again after 40–60 min in liver tissue and, shortly after, in bile duct as the result of EHC. In 
rats treated with cholyltaurine  and rifampicin (Fig. 4), the biliary secretion of [18F]FBCGly was significantly 
inhibited as observed by a delayed disappearance of tracer from liver tissue and reduced radioactivity 
concentrations in the bile duct.  
The analysis of plasma and bile samples (Rats 8–10) showed no fluorine-18 metabolites for up to two hours 
after injection of [18F]FBCGly, and confirmed that the second increase in bile radioactivity concentration 
was due to [18F]FBCGly (Fig. 5a and 5b; the delayed decrease of the radioactivity concentration in the 
collected bile compared to that measured by PET is due to dispersion of the tracer in the sampling 
catheter). 
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3.3 In vitro stability test of FBCGly towards enzymatic de-conjugation by Cholylglycine Hydrolase 
Cholylglycine Hydrolase catalyzed the hydrolysis of cholylglycine by 96% within 5 min at 37 oC, while only 
4% of cholylsarcosine was hydrolyzed after 24 hours. These results are similar to what has previously been 
reported [30]. Under the same conditions, no hydrolysis of FBCGly was observed for up to 24 hours. 
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4. Discussion 
We have developed a radiosynthesis of N-(4-[18F]fluorobenzyl)cholylglycine ([18F]FBCGly), a novel fluorine-
18 labeled bile acid conjugate derived from endogenous cholylglycine. The radiosynthesis is based on 
reductive alkylation of glycine with 4-[18F]fluorobenzaldehyde followed by coupling to endogenous cholic 
acid. The radiosynthesis provides [18F]FBCGly with sufficiently high radiochemical purity and radioactivity 
amount for preclinical evaluation of the tracer, although the radiochemical yield needs to be improved for 
translation of [18F]FBCGly to clinical studies. In the present study, we showed that [18F]FBCGly does not 
metabolize in vivo in rats; only non-metabolized tracer was observed in plasma and bile for up to two hours 
after i.v. injection of the tracer. In addition, we showed that FBCGly is stable towards de-conjugation (for up 
to 24 h) by Cholylglycine Hydrolase from Clostridium perfringens (C. welchii), a bacteria commonly found in 
the human intestinal microflora. De-conjugation is the first step in the intestinal biotransformation of 
endogenous bile acid conjugates and occurs increasingly from the distal small intestine to the terminal 
ileum and, particularly, in the colon [1, 10]. Indeed, as shown here and elsewhere [30], Cholylglycine 
Hydrolase rapidly de-conjugates endogenous cholylglycine. The stability of FBCGly towards de-conjugation 
is believed to be due to the additional substituent, 4-fluorobenzyl, on the nitrogen atom. A similar stability 
was observed for cholylsarcosine (N-methyl-cholylglycine), which has a methyl group on the nitrogen atom, 
and for N-benzyl-ursodeoxycholyltaurine, a derivative of endogenous ursodeoxycholyltaurine with an 
unsubstituted benzyl group on the nitrogen atom [31, 32]. Thus, [18F]FBCGly does not undergo hepatic or 
intestinal metabolism on the timescale of the present PET studies. 
 
The dynamic PET/MR studies in rats revealed that, similar to endogenous bile acid conjugates and 
[11C]cholylsarcosine [20], [18F]FBCGly is rapidly taken up by the liver, secreted into bile, and onwards into 
the small intestine. The EHC of [18F]FBCGly is observed as the reappearance of the tracer in liver tissue, bile 
duct and duodenum measured by PET and analysis of bile samples. [18F]FBCGly did not reappear in arterial 
plasma after its initial clearance, which is in accordance with the EHC of endogenous bile acid conjugates 
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that return from the small intestine to the liver via portal venous circulation [10]. We expect that the 
intestinal absorption of [18F]FBCGly occurs beyond duodenum, since the time between the initial peak and 
the second increase in radioactivity concentration in liver tissue and bile duct is too long (more than 40 
minutes) to be explained solely by duodenal absorption of the tracer. In addition, the EHC of [18F]FBCGly 
sometimes appeared as a relatively narrow peak and sometimes as a very broad peak in the time courses of 
radioactivity concentrations measured by PET (Fig. S1 in Supplementary Material). We attribute this 
observation to a normal variation in intestinal mobility and a gradual absorption of [18F]FBCGly during its 
passage through the small intestine. In some cases (Rat 2 and Rat 6 in Fig. S1), we observed a total of three 
increments in the radioactivity concentrations in liver tissue and bile duct each 50–60 minutes apart. This 
observation indicates that [18F]FBCGly circulates continuously, similar to endogenous bile acid conjugates, 
which are efficiently reabsorbed in the small intestine by more than 90% for each cycle [8, 9].  
 
Because [18F]FBCGly is a conjugated bile acid derivative, it is likely to be fully ionized at physiological pH 
and, hence, requires active transport to cross hepatocyte and enterocyte membranes during its EHC [10, 
33]. Due to the high transport capacity of conjugated bile acids in the liver and the small intestine, the 
molar radioactivity of [18F]FBCGly (13 ± 2 GBq/µmol) is not a significant factor in terms of in vivo transport 
studies. In the hepatocytes, two transporter proteins should be considered in particular for the transport of 
[18F]FBCGly across the canalicular membrane: the BSEP, which constitutes the major driving force for the 
secretion of conjugated bile acids from hepatocytes into bile, and the less specific Multidrug Resistance 
Protein 2 (MRP2).  To investigate which of these two proteins are likely to transport [18F]FBCGly, we used 
rifampicin as inhibitor, because it is known to directly cis-inhibit BSEP without inhibiting MRP2 in rats [34]. 
We found that rifampicin significantly inhibited the biliary secretion of [18F]FBCGly. In accordance with this, 
endogenous cholyltaurine, which is transported to a major extent by rat BSEP [34], also inhibited the biliary 
secretion of [18F]FBCGly significantly. Thus, the BSEP is likely to be a major transporter of [18F]FBCGly from 
hepatocytes into bile, although other canalicular transporter proteins may also be involved. The results also 
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indicate that cholyltaurine inhibits the transport of [18F]FBCGly across the intestinal membrane as observed  
by a delayed EHC of the tracer in rats treated with cholyltaurine (more than 70 min recirculation time) 
compared to untreated rats and rats treated with rifampicin (40–60 min recirculation time). This finding 
suggests that [18F]FBCGly and cholyltaurine compete for one or more of the same transporter proteins  in  
the enterocyte membranes. To what extent individual transporter proteins are involved in the transcellular 
transport of [18F]FBCGly in hepatocytes and enterocytes remain however to be investigated.  
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5. Conclusion 
We have developed a radiosynthesis of a novel fluorine-18 labeled bile acid derivative, N-(4-
[18F]fluorobenzyl)cholylglycine ([18F]FBCGly), and shown by dynamic PET/MR in rats that [18F]FBCGly 
undergoes continuous EHC without metabolizing. To the best of our knowledge, [18F]FBCGly is the first PET 
tracer shown to undergo EHC. Under normal conditions, [18F]FBCGly is subject to a rapid transhepatic 
transport, resulting in high concentrations of the tracer in bile, but it is inhibited by rifampicin and 
endogenous cholyltaurine, which indicate that the BSEP is likely to be involved in the secretion of 
[18F]FBCGly from hepatocyte into bile. We envision that [18F]FBCGly PET can be used as tool for non-
invasive in vivo investigations of the pathological mechanisms of diseases that affect the EHC and of drugs 
inhibiting hepatic and intestinal transport of conjugated bile acid. 
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Figure Legends  
Fig. 1. Radiosynthesis of [18F]FBCGly. Reagents and conditions: i) [18F]KF-K222, dimethylsulfoxide, 105 °C, 10 
min; ii) glycine methyl ester hydrochloride, triethylamine, dimethylsulfoxide, 60 oC, 10 min; iii) sodium 
borohydride, dimethylsulfoxide, 25 oC, 5 min; iv) cholic acid, triethylamine, diethyl phosphoryl cyanide, 
dimethylsulfoxide, 60 oC, 10 min; v) purification, then 0.25 M NaOH, room temperature, 10 min, then 
neutralization with aqueous 70 mM NaH2PO4. 
 
Fig. 2. Typical HPLC chromatograms recorded during radiosynthesis of [18F]FBCGly: (a) shows a 
radiochromatogram of purified [18F]FBCGly ready for injection (HPLC sample collected after step v in Fig. 1); 
(b) shows radio- (full line) and UV- (dotted line) chromatograms of [18F]FBCGly co-injected with unlabeled 
FBCGly for identification of the tracer; (c) shows radiochromatograms of the conversion of [18F]FBA (dotted 
line) into [18F]FBGly-ME (full line; crude sample collected after step iii in Fig. 1); (d) shows a 
radiochromatogram of the in situ conversion of crude [18F]FBGly-ME into [18F]FBCGly-ME (sample collected 
after step iv in Fig. 1). 
 
Fig. 3. Coronal PET/MR images of the time course of distribution of [18F]FBCGly recorded as mean values 
(MBq/mL) in the time intervals indicated during the 120-min PET scan of Rat 1 (240 g; anesthetized with 2% 
isoflurane) after i.v. bolus injection of tracer (28 MBq). All images are of the same slice. 
 
Fig. 4. Time courses of radioactivity concentrations in liver tissue and bile duct (dynamic PET/MR) after i.v. 
bolus injection of [18F]FBCGly (19–33 MBq) in untreated rats (controls; Rats 1–3; n = 3), rats treated with 
cholyltaurine (Rats 4 and 5; n = 2), and rats treated with rifampicin (Rats 6 and 7; n = 2). The insets show the 
first 30 minutes of the curves. The data is represented as mean (SD).  %ID = percent of injected dose. Time 
courses for the individual animals are presented in Supplementary Material. 
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Fig. 5. Results from metabolite analysis of (a) arterial plasma and (b) bile samples collected after i.v. bolus 
injection of [18F]FBCGly in Rat 8 (32 MBq) and Rat 10 (35 MBq), respectively. The radioactivity is decay 
corrected to the time of injection. Fractions 10–12 correspond to non-metabolized [18F]FBCGly. 
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